Open AccessPB1813: EFFICACY OF AZACITIDINE AND VENETOCLAX IN AML PATIENTS MAY BE LIMITED BY INTERACTION WITH POSACONAZOLE AND LACK OF STANDARDISED TREATMENT PROTOCOL. REAL WORLD DATA FROM 3 MAJOR CENTRES IN SINGAPORE.
Author(s) -
Christopher D.,
Abdul Halim N. A.,
Gallardo C. A.,
Lim G. H.,
Jen W. Y.,
Lin C. Y.,
Bingwen E. F.,
Ooi M.,
Chee Y. L.,
Sampath V. S.,
Wong G. C.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850104.80221.19
Subject(s) - azacitidine , venetoclax , medicine , oncology , hypomethylating agent , concomitant , myeloid leukemia , leukemia , chronic lymphocytic leukemia , dna methylation , gene , biochemistry , chemistry , gene expression